About Inotrem
Inotrem is a company based in Paris (France) founded in 2013. Inotrem has raised $122.46 million across 7 funding rounds from investors including Bpifrance, Edmond de Rothschild and Kreos Capital. Inotrem offers products and services including Nangibotide and Monoclonal Antibodies. Inotrem operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and AskBio, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Inotrem S.A
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$122.46 M (USD)
in 7 rounds
-
Latest Funding Round
Not available
-
Investors
Bpifrance
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inotrem
Inotrem offers a comprehensive portfolio of products and services, including Nangibotide and Monoclonal Antibodies.
Treats septic shock and COVID-19 through immunomodulation.
Targets chronic inflammatory diseases via TREM-1 pathway.
People of Inotrem
Unlock access to complete
Unlock access to complete
Funding Insights of Inotrem
Inotrem has successfully raised a total of $122.46M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Inotrem
Inotrem has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, Edmond de Rothschild and Kreos Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt is provided to growth-stage companies across multiple sectors.
|
Locked | Locked | Locked | |
|
Risk capital is provided to life sciences entrepreneurs.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Locked | Locked | Locked |
Investor details for Inotrem
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inotrem
Investment portfolio details for Inotrem
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inotrem
Detailed financials for Inotrem
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inotrem Comparisons
Peer comparison for Inotrem
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inotrem
Inotrem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and AskBio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health
|
Detailed competitors of Inotrem
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inotrem
Complete news archive for Inotrem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inotrem
Inotrem was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Inotrem is headquartered in Paris, France.
Sven Zimmermann is the current CEO of Inotrem.
Inotrem is a funded company, having raised a total of $122.46M across 7 funding rounds to date.
Inotrem was founded in 2013 in Paris, France, and operates in the biotechnology sector. Peptide-based drugs targeting the TREM-1 pathway are developed by the company for conditions such as septic shock and acute myocardial infarction. The lead candidate, Motrem, functions as a TREM-1 inhibitor through its role as a decoy receptor. This 12-amino-acid peptide is currently in phase I clinical trials.
Inotrem's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Inotrem offers Nangibotide and Monoclonal Antibodies.
Inotrem has 13 investors. Key investors include Bpifrance, Edmond de Rothschild, Kreos Capital, Andera Partners, and Crohn's & Colitis Foundation.